Beauvericin inhibits melanogenesis by regulating cAMP/PKA/CREB and LXR-\(\alpha\)/p38 MAPK–mediated pathways

Seung Eun Lee, See-Hyoun Park, Sae Woong Oh, Ju Ah Yoo, Kitae Kwon, Se Jung Park, Jangsoon Kim, Hak Sung Lee, Jae Youl Cho & Jongsung Lee

Melanogenesis is the process of production of melanin pigments that are responsible for the colors of skin, eye, and hair and provide protection from ultraviolet radiation. However, excessive levels of melanin formation cause hyperpigmentation disorders such as freckles, melasma, and age spots. Liver X receptors (LXR) are nuclear oxysterol receptors belonging to the family of ligand-activated transcription factors and physiological regulators of lipid and cholesterol metabolism. In the skin, activation of LXRs stimulates differentiation of keratinocytes and augments lipid synthesis in sebocytes. However, the function of LXRs in melanogenesis has not been clearly elucidated. In addition, although beauvericin, a well-known mycotoxin primarily isolated from several fungi, has various biological properties, its involvement in melanogenesis has not been reported. Therefore, in this study, we examined the effects of beauvericin on melanogenesis and its molecular mechanisms. Beauvericin decreased melanin content and tyrosinase activity without any cytotoxicity. Beauvericin also reduced protein levels of MITF, tyrosinase, TRP1, and TRP2. In addition, beauvericin suppressed cAMP-PKA-CREB signaling and upregulated expression of LXR-\(\alpha\), resulting in the suppression of p38 MAPK. Our results indicate that beauvericin attenuates melanogenesis by regulating both cAMP/PKA/CREB and LXR-\(\alpha\)/p38 MAPK pathways, consequently leading to a reduction of melanin levels.
upregulated by the NF-κB signaling pathway\textsuperscript{9,10}. In contrast, melanogenesis is inhibited through the liver X receptor (LXR)-mediated pathway\textsuperscript{11}.

Liver X Receptors (LXRs) are nuclear oxysterol receptors belonging to the family of ligand-activated transcription factors\textsuperscript{12} and physiological regulators of lipid and cholesterol metabolism\textsuperscript{13,14}. In addition, LXRs are involved in the inflammatory response and immunity\textsuperscript{15}. LXRs have two isoforms: LXR-\(\alpha\), which is highly expressed in the liver and adipose tissue, and LXR-\(\beta\), which is more ubiquitous\textsuperscript{16}. In particular, LXR-\(\alpha\) expression is relatively high in perilesional melanocytes\textsuperscript{18,19} and is involved in regulation of melanogenesis\textsuperscript{20}.

Beauvericin, an important bioactive metabolite of \textit{Cordyceps} species, is a well-known mycotoxin that is primarily isolated from several fungi, such as an entomopathogenic fungus \textit{Beauveria bassiana} and \textit{Fusarium} spp. Beauvericin belongs to the enniatin antibiotic family and its structure is a cyclic hexadepsipeptide that contains three D-hydroxyisovaleric acid residues alternating with three N-methylphenylalanine residues (Fig. 1A). Beauvericin has been reported to have several properties such as insecticidal, antimicrobial, and anti-tumor activities\textsuperscript{21,22}. It exerts its anti-cancer effects by inducing apoptosis in several cancer cells including CCRF-CEM leukemia cells, human non-small cell lung cancer A549 cells, human colon adenocarcinoma Caco-2 cells, and H4IIE hepatoma cells\textsuperscript{23–25}. Beauvericin is also known to have an ionophoric property and regulates translocation of specific ions through cellular channels\textsuperscript{26–30}. In addition, beauvericin has anti-inflammatory effects by inhibiting T cell activation through downregulation of the PI3K/Akt signaling pathway\textsuperscript{31}. Although these various properties of beauvericin are well recognized, its effects on skin biology have not been reported.

In this study, we examined the effects of beauvericin on melanogenesis and its molecular mechanisms.
Results

Beauvericin inhibits melanogenesis in B16F10 cells and human epidermal melanocytes. To examine the effects of beauvericin on melanogenesis, a melanin content assay was performed in mouse melanoma B16F10 cells. As shown in Fig. 1B, beauvericin reduced melanin content in a concentration-dependent manner. In addition, cellular tyrosinase activity was suppressed by beauvericin treatment (Fig. 1C). In these experiments, H89, a specific inhibitor of PKA, and forskolin were used as a negative control and a positive control, respectively. As shown in Fig. 1B,C, forskolin significantly increased melanin content and cellular tyrosinase activity, while H89 significantly reduced them. We found that beauvericin showed no cytotoxic effects at the concentrations tested (Fig. 1D). In a cell-free tyrosinase activity assay, beauvericin suppressed tyrosinase activity (tyrosine hydroxylase and dopa oxidase) concentration-dependently (Fig. 1E). Consistent with these findings, we found that beauvericin reduced melanin content (Fig. 2A) and cellular tyrosinase activity (Fig. 2B) in human epidermal melanocytes. As shown in Fig. 2A,B, while forskolin significantly increased melanin content and cellular tyrosinase activity, H89 significantly reduced them. We also found that beauvericin showed no cytotoxicity at the concentrations treated (Fig. 2C). In addition, using Fontana-Masson staining, we found that treatment with beauvericin reduced the level of melanin in reconstructed epidermis (Fig. 2D). The imaging results of B16F10 cells and human epidermal melanocytes were incubated with the indicated concentration of beauvericin for 24 h or 48 h, imaging analysis was performed. Fk, forskolin; BEA, beauvericin.

Beauvericin regulates expression of melanogenic genes. To investigate the effects of beauvericin on expression of melanogenesis-related genes including MITF, tyrosinase, TRP1, and TRP2, Western blot and real-time PCR analyses were performed. Beauvericin decreased mRNA levels of MITF, tyrosinase, TRP1, and TRP2 (Fig. 3A). In addition, the levels of these proteins were also decreased by beauvericin treatment (Fig. 3B). These results indicate that anti-melanogenic effects of beauvericin are mediated by downregulating the expression of melanogenic genes.
Inhibitory effect of beauvericin on cAMP-related signaling pathway. We found that beauvericin inhibits melanogenesis through the downregulation of MITF, consequently inhibiting expression of tyrosinase, TRP1, and TRP2. It is well known that the cAMP signaling pathway contributes to melanogenesis. Therefore, to examine the involvement of cAMP signaling in the anti-melanogenesis activity of beauvericin, we performed ELISA for protein kinase A (PKA) activity and cAMP and Western blot analysis for phosphorylated CREB. As shown in Fig. 4A, cAMP production was reduced by beauvericin treatment. Activity of PKA (a cAMP-dependent molecule) was also suppressed (Fig. 4B). As expected, beauvericin reduced phosphorylation of CREB, a substrate of PKA (Fig. 3C). These data indicate that beauvericin inhibits melanogenesis by suppressing cAMP-PKA-CREB signaling.

Involvement of MAPKs and NF-κB in the anti-melanogenesis effect of beauvericin. To examine the involvement of MAPKs and NF-κB in the beauvericin-induced inhibition of melanogenesis, Western blot analysis was performed to measure the phosphorylated levels of MAPKs and NF-κB. As shown in Fig. 5, beauvericin reduced the phosphorylated levels of p38 MAPK, but had no effects on phosphorylated levels of NF-κB, ERK, and JNK. These results suggest that beauvericin suppresses melanogenesis by inhibiting the p38 MAPK signaling pathway.

Involvement of liver X receptor-α (LXR-α) in beauvericin-induced depigmentation. In this study, we examined whether beauvericin-induced anti-melanogenesis was related to expression of the LXR-α gene. First, we investigated the effect of beauvericin on the liver X receptor (LXR)-α promoter-luciferase reporter activity. As shown in Fig. 6A, LXR-α promoter-luciferase reporter activity assay showed that LXR-α promoter-luciferase reporter activity was significantly increased following beauvericin treatment in a concentration-dependent manner. In addition, we examined the protein level of LXR-α using Western blot assay. The protein expression of LXR-α was upregulated by beauvericin in a concentration-dependent manner (Fig. 6B). These results suggest that the anti-melanogenic effect of beauvericin is related to the LXR-α signaling pathway.

To further confirm involvement of LXR-α in the anti-melanogenic effects of beauvericin, melanin content and cell viability assays were performed in the presence of LXR-α siRNA. As shown in Fig. 7A, the anti-melanogenic effects of beauvericin were attenuated by transfection with siRNA specific for LXR-α, indicating that beauvericin inhibits melanogenesis by upregulating expression of the LXR-α gene. In this experiment, beauvericin and siRNA transfection showed no cytotoxic effects (Fig. 7B). Similar to the melanin content assay, the reduced cellular tyrosinase activity induced by beauvericin treatment was recovered by LXR-α siRNA transfection (Fig. 7C). We also confirmed the efficacy of the LXR-α siRNA used in these experiments. As shown in Fig. 7D, the protein level of LXR-α was significantly reduced by transfection of LXR-α siRNA. In addition, we examined the effect of LXR-α siRNA transfection on protein levels of MITF and tyrosinase. As expected, the inhibitory effects of beauvericin on expressions of MITF and tyrosinase genes were significantly attenuated by LXR-α siRNA transfection (Fig. 7E). These data indicate that upregulation of LXR-α gene contributes to the effects of beauvericin on melanogenesis.

Effect of liver X receptor-α agonist TO901317 on p38 MAPK phosphorylation. To investigate the involvement of LXR-α signaling in the p38 MAPK activation, we conducted Western blot analysis for phosphorylated p38 MAPK in cells treated with the LXR-α agonist TO901317. First, we investigated the effects of TO901317 treatment on expression of the LXR-α gene. As shown in Fig. 8A, similar to the effects of beauvericin, the expression level of LXR-α gene was increased after treatment with TO901317. Next, we examined the effects
of TO901317 treatment on phosphorylation of p38 MAPK. As shown in Fig. 8B, the phosphorylation level of p38 MAPK was significantly decreased by TO901317 treatment in a time-dependent manner. These results indicate that LXR-α and the p38 MAPK pathway are reciprocally related and suggest that the depigmenting effects of

Figure 4. Suppression of cAMP-related signaling in response to treatment with beauvericin. (A) Intracellular cAMP levels were analyzed using a cAMP assay ELISA kit. Cells were treated with the indicated concentration of beauvericin for 4 h. Results were confirmed from at least three independent experiments and values represent the means ± SEM. *P < 0.05 vs. untreated control. (B) Activity of PKA, the downstream molecule of cAMP, was assayed using an ELISA kit. Cells were treated with the indicated concentration of beauvericin for 4 h. Results were confirmed from at least three independent experiments and values represent the means ± SEM. *P < 0.05 vs. untreated control. (C) Phosphorylation levels of CREB were determined by Western blot analysis. Cells were treated with 10 μM beauvericin for the indicated time and the level of CREB phosphorylation was analyzed. Equivalent amounts of protein were analyzed for each condition. Results were confirmed from at least three independent experiments and values represent the means ± SEM. *P < 0.05 vs. untreated control. FK, forskolin; BEA, beauvericin.

Figure 5. Effects of beauvericin on phosphorylation of MAPKs and NF-κB in B16F10 cells. Cells were treated with 10 μM beauvericin for the indicated time and the phosphorylation levels of proteins were determined by Western blot analysis. Results were confirmed from at least three independent experiments and values represent the means ± SEM. *P < 0.05 vs. untreated control. p38, p38 MAPK; BEA, beauvericin.
beauvericin are mediated through upregulation of LXR-\(\alpha\), which subsequently inhibits phosphorylation of p38 MAPK resulting in downregulation of melanogenic genes.

To further examine the relationship of LXR-\(\alpha\) and the cAMP-PKA-CREB signaling pathway in beauvericin-induced anti-melanogenesis activity, we investigated the effects of H89, a PKA inhibitor, on protein levels of LXR-\(\alpha\) and phosphorylation levels of p38 MAPK. As shown in Fig. 8C, H89 increased protein levels of LXR-\(\alpha\) but decreased the phosphorylation level of p38 MAPK. These data suggest that PKA operates upstream of LXR-\(\alpha\) as a negative regulator, and p38 MAPK is a downstream signaling molecule of LXR-\(\alpha\). In addition, although H89 treatment suppressed PKA activity, TO901317 (LXR-\(\alpha\) agonist) did not affect PKA activity (Fig. 8D). Moreover, TO901317 showed no effects on phosphorylation of CREB, a downstream molecule of PKA. Collectively, these results indicate that beauvericin inhibits cAMP/PKA/CREB signaling and LXR-\(\alpha\)/p38 MAPK signaling, leading to inhibition of melanogenesis (Fig. 9).

**Discussion**

Many researchers have investigated the mechanisms and regulation of skin pigmentation with the aim of treating or preventing hyperpigmentation skin problems\(^1\). However, several anti-melanogenic agents have shown adverse effects and cytotoxicity on skin cells. Therefore, it is necessary to fully understand the mechanism in order to develop more effective and safe agents.

In this study, we examined the effects of beauvericin on melanogenesis as well as the involved mechanisms. We demonstrated that beauvericin regulated melanogenesis by downregulating MITF expression through suppression of cAMP/PKA/CREB signaling and activation of LXR-\(\alpha\)/p38 MAPK signaling. In addition, we demonstrated that LXR-\(\alpha\) is a downstream molecule of PKA and operates upstream of p38 MAPK in beauvericin-induced anti-melanogenesis.

Several signaling pathways have been involved in pigmentation. Among the various pathways regulating melanogenesis, cyclic AMP is a key physiologic signaling molecule regulating pigmentation\(^4\). Cyclic AMP leads to activation of PKA, followed by phosphorylation of CREB transcription factor. CREB stimulates expression of the MITF gene, leading to an increase of melanin levels\(^32\). In this study, beauvericin reduced cAMP levels and suppressed CREB phosphorylation as well as PKA activity. These data suggest that the cAMP-PKA-CREB pathway may be responsible for beauvericin-induced anti-melanogenesis.

The MAPKs (p38 MAPK, ERK, JNK) and NF-\(\kappa\)B are components of other signaling pathways for melanogenesis\(^11\). In this study, beauvericin inhibited phosphorylation of p38 MAPK, but had no effect on JNK, ERK, and NF-\(\kappa\)B, indicating that p38 MAPK signaling is related in the depigmenting effects of beauvericin.

LXRs, consisting of LXR-\(\alpha\) and LXR-\(\beta\), are another type of melanogenic signaling molecule. These proteins are nuclear receptors that are involved in lipid and cholesterol metabolism and anti-inflammatory activities\(^3,13\). In particular, LXR-\(\alpha\) is highly expressed in melanocytes from perilesional skin of patients with vitiligo and inhibits melanogenesis\(^3,19\). In this study, we showed that beauvericin increased expression of the LXR-\(\alpha\) gene. Increased melanin content induced by beauvericin was attenuated by knockdown of the LXR-\(\alpha\) gene. Furthermore, knockdown of LXR-\(\alpha\) rescued the reduction of MITF and tyrosinase gene expression induced by beauvericin. These results suggest the involvement of LXR-\(\alpha\) signaling in beauvericin activity.

This study demonstrated the involvement of three signaling pathways (cAMP/PKA/CREB pathway, p38 MAPK signaling, and LXR-\(\alpha\) signaling) in the depigmenting effect of beauvericin. We therefore studied the hierarchy and relationship among these signaling pathways. Although TO901317 (LXR-\(\alpha\) agonist) reduced phosphorylation levels of p38 MAPK, it did not affect PKA activity or the phosphorylation level of CREB, a downstream molecule of PKA. In addition, H89 (a PKA inhibitor) upregulated expression of LXR-\(\alpha\) and suppressed phosphorylation of p38 MAPK. These data suggest that PKA operates upstream of LXR-\(\alpha\) as a negative regulator, and
p38 MAPK is a downstream signaling molecule of LXR-α. Collectively, these results indicate that the beauvericin effect is mediated by inhibiting cAMP/PKA/CREB pathway and activating LXR-α/p38 MAPK pathway, consequently leading to inhibition of melanogenesis (Fig. 8).

Recently, our group demonstrated the anti-melanogenic mechanisms of resorcinol, which is one of the phenolic components of argan oil36. Similar to beauvericin, resorcinol suppressed the enzymatic activity of tyrosinase. In addition, it activated the p38 MAPK pathway, leading to inhibition of melanogenesis. However, the difference was that, while resorcinol inhibited cAMP signaling, beauvericin had no effects on it. This indicates that the molecular target of beauvericin is more specific than resorcinol, suggesting the possibility that the side effects of beauvericin are not greater than those of resorcinol. In addition, it suggests that beauvericin may be selectively used as an inhibitor of p38 MAPK signaling in treating hyperpigmentation disorders.

Melanin scavenges free radicals, chelates metal cations and cellular toxins, and consumes intracellular oxygen, thus leading to hypoxia. Owing to these properties, melanin has various physiological functions3,27,34. Therefore, in normal melanocytes, melanin protects against ultraviolet radiation and oxidative stress. Melanin is also a marker of melanocyte differentiation and affects behavior of melanocytes and their surrounding environment. However, in melanomas, melanogenesis is not properly regulated, inducing an oxidative microenvironment with secondary mutagenic effects and producing highly immunosuppressive intermediates39–42. These all can potentially contribute to more aggressive cancers. In addition, melanin can cause resistance of melanoma cells to various types of therapy including radiotherapy, immunotherapy, and chemotherapy39–42. In this study, we demonstrated that beauvericin regulates melanogenesis in both melanoma cells and normal cells. Beauvericin has also been reported to have several beneficial properties such as insecticidal, antimicrobial, anti-tumor, and anti-inflammatory activities21,22,31. The results of our study suggest that beauvericin may be used as an agent to enhance the susceptibility of melanoma cells to various types of therapy as well as to treat hyperpigmentation disorders.

In conclusion, the results of this study demonstrate that beauvericin inhibits melanogenesis through inhibition of cAMP/PKA signaling, which induces upregulation of LXR-α and inhibition of p38 MAPK phosphorylation.
Materials and Methods

Cell culture. B16F10 cells (Cascade Biologics, Portland, OR, USA), a mouse melanoma cell line, were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics (penicillin/ streptomycin) in a humidified 5% CO₂ atmosphere at 37 °C. Cultured human epidermal melanocytes (neonatal, moderately pigmented donor) were obtained from Cascade Biologics (Portland, OR, USA) and maintained in Medium 254 (Cascade Biologics) supplemented with Human Melanocyte Growth Supplement (HMGS) at 37 °C in a humidified atmosphere containing 95% air/5% CO₂. For experiments, melanocytes were used at passage 2 or 5 and maintained in Medium 254 (Cascade Biologics) supplemented with HMGS.

Assay for cell viability. The effect of beauvericin (Sigma-Aldrich, St. Louis, MO, USA) on the viability of B16F10 cells or human epidermal melanocytes was determined using cell counting kit-8 (CCK-8, Dojindo, Japan). B16F10 cells cultured in 6-well plates were treated with various concentrations (1 μM, 5 μM, 10 μM) of beauvericin and incubated at 37 °C for 24 h. CCK-8 (8 μL/well) was added to each well and the plates were incubated at 37 °C for a further 2 h. The supernatant was added to 96-well plates and the absorbance was measured at 450 nm using a microplate reader (Synergy HTX Multi-Mode Reader, Biotek, VT, USA).

MBTH (3-methyl-2-benzothiazolinonehydrazone hydrochloride) assay for tyrosinase (dopa oxidase) activity. B16F10 cells or human epidermal melanocytes were incubated in 6-well plates and incubated at 37 °C overnight. Cells were treated with beauvericin for 24 h and then washed, harvested with PBS, and centrifuged for 5 min at 13,000 rpm. The supernatant was discarded, and the cells were lysed using a sonicator.
with lysis buffer (50 mM pH 6.8 sodium phosphate, 1% Triton X-100, and 1 mM phenylmethanesulfonyl fluoride [PMSF]) for 15 min. Reaction buffer (50 mM sodium phosphate pH 7.1, 2% (by vol.) N, N-dimethylformamide, 1 mM L-dopa, and 6 mM MBTH, final pH of 6.9) was added to the 96-well plate to determine the activity of tyrosinase. After incubation for 10 min at 37 °C, the amount of generated pink product was measured by absorbance at 505 nm using a microplate reader.

**Assay for tyrosine hydroxylase activity.** Tyrosine hydroxylase assay was performed as previously described. Firstly, tetrahydrobiopterin (BH4), iron(II) sulfate, and cell extract containing tyrosine hydroxylase were mixed (mixture A) and incubated for 10 min on ice. During this incubation, tyrosine, HEPES (10 mM), and sodium periodate were mixed to make a second mixture (mixture B). A and B were combined in a 96-well plate in a 1:1 ratio to induce reaction (final concentrations: BH4 (0.25 mM), iron (2.5 μM), tyrosine (50 μM), and sodium periodate (100 μM)). Absorbance was immediately measured at 475 nm using a microplate reader. After an initial mixing for 3 s, the plate was read every 30 s for 30 min at 37 °C.

**Assay for melanin content.** Cells were seeded in 6-well plates and incubated at 37 °C overnight. Cells were treated with beauvericin for 24 h and then washed, and harvested with PBS, and centrifuged for 5 min at 13,000 rpm. The supernatant was discarded and the cells were dissolved in 1 mL of a mixture of Soluene-350:water = 9:1 (v/v) by heating in a boiling water bath for 45 min as described previously. The melanin content was measured by absorbance at 500 nm using a microplate reader.

**mRNA analysis for target genes.** TRIzol reagent (ThermoFisher Scientific, Waltham, MA, USA) and moloney murine leukemia virus reverse transcriptase (ThermoFisher Scientific) were used to extract total RNA from cells and synthesize cDNA, respectively. An ABI7900HT Real-time PCR Instrument (Applied Biosystems, Waltham, MA, USA) was introduced for real-time RT-PCR analysis. The real-time RT-PCR analysis was conducted using TaqMan probes (Applied Biosystems) including Tyrosinase (ID: Mm00495818_m1), MITF (ID: Mm01182484_m1), TRP-1 (ID: Mm01268471_m1), TRP-2 (ID: Mm01225584_m1), hypoxanthine-guanine phosphoribosyltransferase (HPRT) (Mm00446966_m1), 18S (Mm04277571_s1), and GAPDH (ID: Mm99999915_g1). The PCR reaction was done with parameters as follows: 50 °C for 2 min, 60 °C for 30 min, and 95 °C for 5 min, and then 45 cycles of 94 °C for 20 s and 60 °C for 1 min as described previously. The PCR results were normalized to the expression level of three housekeeping genes (GAPDH, 18S and HPRT) using ABI sequence detector software version 2.0 (Applied Biosystems). Results were confirmed from at least three independent experiments.

**Small interference RNA (siRNA) transfection.** ON-TARGETplus SMARTpool mouse Nr1h3 (LXR-α) siRNA (L-040649-01-0005) and ON-TARGETpuls Non-targeting pool (D-001810-10-20) were synthesized by Dharmaco Research (Lafayette, CO, USA). The cells were transfected with 25 nM of the indicated siRNAs for 48 h using DarmaFECT transfection agent (Dharmacon Research) according to the manufacturer's instructions.
Western blot analysis. B16F10 cells were seeded in 60-mm dishes. The cells were harvested and centrifuged for 5 min at 13,000 rpm. The supernatant was discarded and the cells were lysed with RIPA lysis buffer [25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS (ThermoFisher Scientific, Waltham, MA, USA)] containing Halt protease and phosphatase inhibitor cocktail (ThermoFisher Scientific). Proteins extracted from the cells were separated by 8–10% SDS electrophoresis and transferred onto nylon membranes. The membranes were blocked with 5% skim milk for 1 h and then incubated with primary antibodies at 4 °C overnight. The membranes were washed three times in Tris-buffered saline (TBS) containing Tween 20 and probed with secondary antibodies for 1 h at room temperature. The blots were visualized using ECL Western Blotting Reagents.

cAMP assay. The cAMP level was determined using a cAMP immunoassay kit (Cayman, Ann Arbor, MI, USA). In brief, B16F10 cells were incubated with the indicated concentration of beauvericin for 4 h. The cells were harvested and lysed in HCl (0.1 M) to suppress phosphodiesterase activity and incubated at room temperature for 30 min. The supernatants were collected in e-tubes. A constant concentration of cAMP-acetylcholinesterase (AchE) conjugate (Tracer) and the supernatant were added to a 96-well plate. After incubation at 4 °C for 18 h and washing to remove unbound cAMP, Ellman's reagent was added to the wells to measure the activity of cAMP. The absorbance was read at 405 nm using a microplate reader. The intensity of the color, which was proportional to the amount of cAMP Tracer, was inversely proportional to the concentration of cAMP in the wells.

Assay for β-galactosidase and luciferase reporter activities. The LXR-α promoter-luciferase reporter was generated by our group as follows. A region of the mouse LXR-α promoter from −926 to +413 (NCBI Reference Sequence: NC_000068.7) was chemically synthesized and cloned into the pGL4.11 (luc2P) vector (Promega Corporation, Madison, WI, USA) using two restriction enzyme sites (SpeI and XhoI). Cells were seeded in 6-well plates and incubated at 37 °C overnight. The cells were co-transfected with 1 μg LXR-α promoter-luciferase reporter and 1 μg β-galactosidase vector (Promega Corporation) using 5 μg polyethylenimine (Sigma-Aldrich, St. Louis, MO, USA) to assay for LXR-α promoter-luciferase activity. At 4 h after transfection, the cells were cultured in new medium for 24 h and then incubated in the presence of beauvericin for 24 h. β-galactosidase activity was assayed using the β-galactosidase Enzyme Assay System with Reporter Lysis Buffer (Promega Corporation). The cells were harvested with PBS and lysed with Reporter Lysis Buffer (Promega Corporation). The cells were centrifuged and the supernatants were transferred to 96-well plates to assay for β-galactosidase activity. Color development was stopped by addition of 1 M sodium carbonate to the wells and the absorbance at 420 nm was measured using a microplate reader to assay for β-galactosidase activity. Luciferase activity was assayed using the Luciferase activity Assay System (Promega Corporation). The cells were harvested with PBS and lysed with Reporter Lysis Buffer (Promega Corporation). The cells were centrifuged and the supernatants were transferred to 96-well plates. Luciferase assay substrate and Luciferase assay buffer were added to the wells and luminescence was determined using a microplate reader. Activity was expressed as the ratio of LXR-α dependent firefly luciferase activity to β-galactosidase activity.

Assay for protein kinase A (PKA). PKA activity was evaluated using a PKA activity assay kit purchased from Enzo Life Sciences, Inc (Farmingham, NY, USA). B16F10 cells were treated with the indicated concentration of beauvericin for 4 h. The cells were harvested and washed with PBS and lysed by incubation in lysis buffer at 4 °C for 10 min. The cell lysates were centrifuged at 15000 rpm for 15 min at 4 °C to obtain supernatant as a protein source. The protein samples and diluted ATP were added to 96-well plates which were pre-coated with substrate peptide for PKA and the plates were incubated at 30 °C for 90 min. The reaction was stopped by removing the contents from the wells. The phosphospecific substrate antibody was added to each well and the plates were incubated at 30 °C for 60 min. The wells were washed with washing buffer four times and incubated with anti-rabbit IgG for 30 min at room temperature. The wells were washed again four times with washing buffer and TMB substrate was added. The plates were incubated at 30 °C for 60 min to develop the color. Finally, stop solution 2 was added to the wells to stop the color development and the absorbance at 450 nm was measured using a microplate reader.

Histochemical staining of reconstructed epidermis. Reconstructed human epidermis (MatTek Corporation, Ashland, MA, USA) consisting of normal human-derived epidermal keratinocytes and NHEM was cultured to form a multilayer and become highly differentiated. Keratinocytes and NHEM in the reconstructed human epidermis were derived from Asian skin types. Reconstructed epidermis was incubated in medium containing beauvericin (10 μM) for 2 weeks. Compound added to the lower well of the reconstructed epidermal system could penetrate through the membrane to reach the basal cells. The medium containing beauvericin was replaced every other day. To visualize melamin pigments, the epidermis was fixed with 4% formalin in PBS, followed by Fontana–Masson staining. Briefly, the epidermal cells were washed twice with dH2O and then incubated with Fontana ammoniacal silver solution (American MasterTech, Lodi, CA, USA) at 37 °C for 1 h. For staining of the reconstructed epidermis, Fontana–Masson Staining Kit (American MasterTech) was used according to the manufacturer’s instructions. Quantification of Fontana-Masson staining was performed using Image J software. A total of 81 cells were analyzed per condition (three microscopic fields per condition, nine cells per microscopic field, three different experiments).

Statistical analysis. All of the data are expressed as means ± standard error of the mean (SEM). Differences between two groups were performed using Student's t test. The comparison between multiple groups was performed using the one way analysis of variance (ANOVA), and it was followed by the Tukey's multiple-comparison test for which the GraphPad Prism (5.0) (GraphPad, La Jolla, CA, U.S.A.) was used. Statistical significance was considered when the p value is less than 0.05.
Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary Information files).

References
1. D’Mello, S. A., Finlay, G. J., Baguley, B. C. & Askarian-Amiri, M. E. Signaling Pathways in Melanogenesis. Int J Mol Sci 17, 18, https://doi.org/10.3390/ijms17071144 (2016).
2. Slominski, A., Tobin, D. J., Shubara, S. & Wortsman, J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84, 1155–1228 (2004).
3. Pillaiyar, T., Manickam, M. & Jung, S. H. Downregulation of melanogenesis: drug discovery and therapeutic options. Drug Discov Today 22, 282–298, https://doi.org/10.1016/j.drudis.2016.09.016 (2017).
4. Rodríguez, C. I. & Setaluri, V. Cyclic AMP (cAMP) signaling in melanocytes and melanoma. Arch Biochem Biophys 563, 22–27, https://doi.org/10.1016/j.abb.2014.07.003 (2014).
5. Vachtelen, J. & Borovansky, J. “Transcription physiology” of pigment formation in melanocytes: central role of MITF. Exp Dermatol 19, 617–627 (2010).

10. Sun, L. et al. The melanogenesis alteration effects of Achillea millefolium L. essential oil and linalyl acetate: involvement of oxidative stress and the INK and ERK signaling pathways in melanoma cells. PLoS One 9, e95186, https://doi.org/10.1371/journal.pone.0095186 (2014).
11. Yoon, H. S. et al. Involvement of extracellular signal-regulated kinase in nobiletin-induced melanogenesis in murine B16/F10 melanoma cells. Biocat Biotechnol Biochim 71, 1781–1784, https://doi.org/10.1271/bbb.70068 (2007).
12. Sun, M. et al. Downregulation of melanogenesis: drug discovery and therapeutic options. J Med Chem 59, 5927–5943, https://doi.org/10.1021/acs.jmedchem.6b00616 (2016).
13. Hong, C. & Tontonoz, P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov 13, 433–444, https://doi.org/10.1038/nrd4280 (2014).
14. Gabbi, C., Warner, M. & Gustafsson, J. A. Action mechanisms of Liver X Receptors. Front Endocrinol 6, 13, https://doi.org/10.3389/fendo.2015.00013 (2015).
15. Prosperini, A., Juan-García, A., Font, G. & Ruiz, M. J. Beauvericin-induced cytotoxicity via ROS production and mitochondrial damage in Caco-2 cells. Toxicol Lett 222, 204–211, https://doi.org/10.1016/j.toxlet.2013.07.005 (2013).
16. Kumar, R., Parsad, D., Kanwar, A. J. & Kaul, D. Altered levels of LXR-alpha: crucial implications in the pathogenesis of vitiligo. Exp Dermatol 13, 1063–1071, https://doi.org/10.1111/j.1600-0625.2009.00940.x (2010).
17. Lee, C. S. et al. Liver X receptor activation inhibits melanogenesis through the acceleration of ERK-mediated MITF degradation. J Invest Dermatol 133, 1063–1071, https://doi.org/10.1111/jid.2012.409 (2013).
18. Wang, G. & Xu, L. Beauvericin, a bioactive compound produced by fungi: a short review. Molecules 17, 2357–2377, https://doi.org/10.3390/molecules17032367 (2012).
19. Xiao, J. H. & Zhong, J. J. Secondary metabolites from Cordyceps species and their antitumor activity studies. Recent Pat Biotechnol 1, 123–137 (2007).
20. Liu, H. L. et al. Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells. Cancer Lett 230, 248–259, https://doi.org/10.1016/j.canlet.2004.12.044 (2005).
21. Lu, C. L., Lin, H. I., Chen, B. F. & Jow, G. M. Beauvericin-induced cell apoptosis through the mitogen-activated protein kinase pathway in human nonsmall cell lung cancer A549 cells. J Toxicol Sci 41, 429–437, https://doi.org/10.2131/jts.41.429 (2012).
22. Kumar, R., Parsad, D., Kaul, D. & Kanwar, A. J. Liver X receptor expression in human melanocytes, does it have a role in the pathogenesis of vitiligo? Exp Dermatol 19, 62–64, https://doi.org/10.1111/j.1600-0625.2009.00940.x (2010).
23. Cheng, C. E., Tsai, M. C. & Jow, G. M. Induction of calcium influx from extracellular fluid by beauvericin in human leukemia cells. Biochem Biophys Res Commun 340, 134–139, https://doi.org/10.1016/j.bbrc.2005.11.166 (2006).
24. Kouri, K., Duchen, M. R. & Lemmens-Gruber, R. Effects of beauvericin on the metabolic state and iconic homeostasis of ventricular myocytes of the guinea pig. Chem Res Toxicol 18, 1661–1668, https://doi.org/10.1021/tx050096g (2005).
25. Lemmens-Gruber, R. et al. The effect of the Fusarium metabolite beauvericin on electromechanical and -physiological properties in isolated smooth and heart muscle preparations of guinea pigs. Myocpatholog 149, 5–12 (2000).
26. Nakajyo, S. et al. Inhibitory effect of beauvericin on a human K+–induced tonic contraction in guinea-pig taenia coli. Jpn J Pharmacol 45, 317–325 (1987).
27. Tang, C. Y., Chen, Y. W., Jow, G. M., Chou, C. I. & Jeng, C. J. Beauvericin activates Ca2+ -activated Cl- currents and induces cell deaths in Xenopus oocytes via influx of extracellular Ca2+. Chem Res Toxicol 18, 825–833, https://doi.org/10.1021/tr010473d (2005).
28. Wu, X. et al. Beauvericin ameliorates experimental colitis by inhibiting activated T cells via downregulation of the PI3K/Akt signaling pathway. PLoS One 8, e83013, https://doi.org/10.1371/journal.pone.0083013 (2013).
29. Lee, C. S. et al. A novel adamantyl benzylbenzamide derivative, AP736, suppresses melanogenesis through the inhibition of cAMP-PAK-CREB-activated microphthalmia-associated transcription factor and tyrosinase expression. Exp Dermatol 22, 762–766, https://doi.org/10.1111/exd.12248 (2013).
30. Sun, M. et al. G protein-coupled estrogen receptor enhances melanogenesis via cAMP-protein kinase (PKA) by upregulating microphthalmia-related transcription factor-tyrosinase in melanoma. J Steroid Biochem Mol Biol 165, 236–246, https://doi.org/10.1016/j.jsbmb.2016.06.012 (2017).
31. Lee, H. Y. et al. Anti-Melanogenic Activity of Gagumin D, a Highly Oxygenated Diterpenoid from the Marine Sponge Phorbas sp., via Modulating Tyrosinase Expression and Degradation. Mar Drugs 14, https://doi.org/10.3390/md14110212 (2016).
32. Oh, T. L. et al. Plumbagin Suppresses alpha-MSH-Induced Melanogenesis in B16F10 Mouse Melanoma Cells by Inhibiting Tyrosinase Activity. Int J Mol Sci 18, https://doi.org/10.3390/ijms18020320 (2017).
36. Kang, M. et al. Anti-melanogenic effects of resorcinol are mediated by suppression of cAMP signaling and activation of p38 MAPK signaling. *Biosci Biotechnol Biochem*, https://doi.org/10.1080/09168451.2018.1459176 (2018).

37. Slominski, A., Zmijewski, M. A. & Pawelek, J. L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. *Pigment Cell Melanoma Res* 25, 14–27 (2012).

38. Slominski, A. et al. The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways. *Arch Biochem Biophys* 563, 79–93 (2014).

39. Brożyna, A. A., Jóźwicki, W., Roszkowski, K., Filipiak, J. & Slominski, A. T. Melanin content in melanoma metastases affects the outcome of radiotherapy. *Oncotarget* 7, 17844–17853 (2016).

40. Brożyna, A. A., Jóźwicki, W., Carlson, J. A. & Slominski, A. T. Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. *Hum Pathol* 44, 2071–2074 (2013).

41. Brożyna, A. A., VanMiddlesworth, L. & Slominski, A. T. Inhibition of melanogenesis as a radiation sensitizer for melanoma therapy. *Int J Cancer* 123, 1448–1456 (2008).

42. Slominski, A., Zbytek, B. & Slominski, R. Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. *Int J Cancer* 124, 1470–1477 (2009).

43. Winder, A. J. & Harris, H. New assays for the tyrosine hydroxylase and dopa oxidase activities of tyrosinase. *Eur J Biochem* 198, 317–326 (1991).

44. Vermeer, L. M., Higgins, C. A., Roman, D. L. & Doorn, J. A. Real-time monitoring of tyrosine hydroxylase activity using a plate reader assay. *Anal Biochem* 432, 11–15 (2013).

45. Ozeki, H., Ito, S., Wakamatsu, K. & Hirobe, T. Chemical characterization of hair melanins in various coat-color mutants of mice. *J Invest Dermatol* 105, 361–366 (1995).

Acknowledgements
This work was partly supported by a grant from Kolmar BNH Co., Ltd., Republic of Korea and by a grant from the the Technology development Program (S2556122) funded by the Korean Ministry of SMEs and Startups.

Author Contributions
S.E.L., S.H.P., J.Y.C. and J.L. devised, performed, and oversaw experiments, analyzed data, and contributed to writing the manuscript; S.E.L., S.H.P., S.W.O., J.A.Y., K.K., S.J.P., J.K. and H.S.L. performed experiments and analyzed data; S.E.L., S.H.P., J.Y.C., and J.L. provided analysis and discussion. All authors reviewed and approved the final version of the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-33352-8.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018